Zai Lab (NASDAQ:ZLAB) CEO Ying Du Sells 50,000 Shares

Posted by Brian Himes on May 16th, 2026

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB – Get Free Report) CEO Ying Du sold 50,000 shares of Zai Lab stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $20.09, for a total transaction of $1,004,500.00. Following the transaction, the chief executive officer directly owned 1,122,626 shares of the company’s stock, valued at $22,553,556.34. The trade was a 4.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Ying Du also recently made the following trade(s):

On Monday, April 6th, Ying Du sold 2,653 shares of Zai Lab stock. The shares were sold at an average price of $20.45, for a total transaction of $54,253.85.
On Thursday, April 2nd, Ying Du sold 5,576 shares of Zai Lab stock. The shares were sold at an average price of $20.39, for a total transaction of $113,694.64.

Zai Lab Trading Up 1.3%

Shares of ZLAB opened at $20.59 on Friday. The firm has a market capitalization of $2.34 billion, a P/E ratio of -12.71 and a beta of 0.85. Zai Lab Limited Unsponsored ADR has a 12-month low of $15.96 and a 12-month high of $44.34. The firm has a fifty day moving average price of $20.34 and a 200-day moving average price of $19.82.

Zai Lab (NASDAQ:ZLAB – Get Free Report) last released its quarterly earnings data on Wednesday, April 1st. The company reported ($0.50) earnings per share for the quarter. The firm had revenue of $99.61 million during the quarter. Zai Lab had a negative net margin of 39.29% and a negative return on equity of 24.32%. Analysts predict that Zai Lab Limited Unsponsored ADR will post -2.22 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ZLAB has been the subject of a number of recent research reports. JPMorgan Chase & Co. reduced their target price on shares of Zai Lab from $39.00 to $32.00 and set an “overweight” rating for the company in a report on Wednesday, March 18th. Wall Street Zen downgraded shares of Zai Lab from a “hold” rating to a “sell” rating in a report on Saturday. Jefferies Financial Group upgraded shares of Zai Lab to a “strong-buy” rating in a report on Monday, January 19th. Weiss Ratings downgraded shares of Zai Lab from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday. Finally, Citigroup reduced their target price on shares of Zai Lab from $47.00 to $44.00 and set a “buy” rating for the company in a report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $45.83.

Check Out Our Latest Stock Analysis on ZLAB

Hedge Funds Weigh In On Zai Lab

An institutional investor recently raised its position in Zai Lab stock. SG Americas Securities LLC boosted its position in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB – Free Report) by 6.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 10,396 shares of the company’s stock after buying an additional 642 shares during the period. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 41.65% of the company’s stock.

Zai Lab Company Profile

(Get Free Report)

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.